Table II.
Item | Baseline | Hospitalized treatment period |
Follow-up time point |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2 h | 12 h | 24 h | 72 h | 7 d/discharge | 1 m | 3 m | 6 m | 9 m | 12 m | ||
History | ○ | ○ | ○ | ○ | ○ | ||||||
Inclusion/exclusion criteria | ○ | ||||||||||
Informed consent | ○ | ||||||||||
Drug distribution | ○ | ○ | ○ | ○ | |||||||
ECG | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |||
cTNI and CKMB | ○ | ○ | |||||||||
NT-ProBNP | ○ | ○ | ○ | ○ | ○ | ||||||
Hematology | ○ | ○ | ○ | ○ | ○ | ||||||
Urinalysis | ○ | ○ | ○ | ○ | ○ | ||||||
Stool occult blood test | ○ | ○ | ○ | ○ | ○ | ||||||
Echocardiogram | ○ | ○ | ○ | ||||||||
Holter | ○ | ○ | ○ | ||||||||
Evaluate clinical end point events | ○ | ○ | ○ | ||||||||
Outpatient follow-up | ○ | ○ | ○ | ○ |
cTNI, cardiac troponin I; CKMB, creatine kinase–muscle/brain; NT-ProBNP, N-terminal pro–B-type natriuretic peptide.